Loading…
Edwards Lifesciences Corporation is projected to rise to $109.96 by 2027, a +19% move from its current price of $92.21. EW is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $91.02 | $92.24 | $93.48 | +0.04% |
| Jul 14 | $90.55 | $92.28 | $94.04 | +0.07% |
| Jul 15 | $90.20 | $92.31 | $94.47 | +0.11% |
| Jul 16 | $89.91 | $92.34 | $94.84 | +0.15% |
| Jul 17 | $89.66 | $92.38 | $95.18 | +0.18% |
| Jul 18 | $89.44 | $92.41 | $95.48 | +0.22% |
| Jul 19 | $89.24 | $92.45 | $95.77 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $89.24 | $92.45 | $95.77 | +0.26% |
| Week 2 | $88.17 | $92.68 | $97.43 | +0.51% |
| Week 3 | $87.41 | $92.92 | $98.78 | +0.77% |
| Week 4 | $86.81 | $93.16 | $99.97 | +1.03% |
| Week 5 | $86.31 | $93.40 | $101.07 | +1.29% |
| Week 6 | $85.88 | $93.64 | $102.09 | +1.55% |
| Week 7 | $85.50 | $93.88 | $103.07 | +1.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation (EW) is a healthcare stock currently priced at $94.37. It has a market capitalization of $54.34B and is ranked 286. The price outlook from the forecast shows a neutral start in 2026 with an average near the current level, followed by a bullish longer‑term trajectory through 2050 as averages rise and upside potential expands."
A major floor 16.3% below — a decisive break under it would weaken the trend.
The nearest floor, 7.7% below — buyers have tended to step in here.
The nearest ceiling, 3.2% above — a clean break opens room to run.
A major ceiling 9.4% above — clearing it would confirm fresh momentum.
Key EW support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EW market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $93.44 | Sell | $92.64 | Sell |
| MA 10 | $92.60 | Sell | $92.11 | Buy |
| MA 20 | $89.90 | Buy | $90.53 | Buy |
| MA 50 | $86.35 | Buy | $87.46 | Buy |
| MA 100 | $84.12 | Buy | $85.27 | Buy |
| MA 200 | $82.92 | Buy | $83.07 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.36 | Neutral |
| Stoch RSI (14) | 35.14 | Neutral |
| CCI (20) | 57.13 | Neutral |
| Williams %R (14) | -31.94 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 6.05 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 68.06 | Neutral |
| TRIX (15) | 0.33 | Buy |
| Awesome (5,34) | 4.97 | Buy |
| Ultimate (7,14,28) | 60.58 | Neutral |
| Momentum (10) | 2.49 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 92.91 | Sell |
| ADX (14) | 21.51 | Buy |
| ATR (14) | 1.20 | Info |
The 30‑day technical picture is bullish in sentiment with RSI14 at 70, and moving averages trending higher above trend. The SMA50 is $85.23 and the SMA200 is $82.45, indicating positive near‑term momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $75.87 | $92.21 | $121.08 | 0% | Neutral | |
| $90.06 | $109.96 | $140.36 | +19% | Neutral | |
| $91.94 | $114.36 | $149.94 | +24% | Bullish | |
| $104.36 | $131.82 | $176.51 | +43% | Bullish | |
| $116.11 | $148.64 | $202.61 | +61% | Bullish | |
| $137.22 | $177.81 | $246.21 | +93% | Bullish | |
| $159.29 | $208.74 | $293.14 | +126% | Bullish | |
| $160.76 | $212.89 | $302.84 | +131% | Bullish | |
| $172.81 | $231.13 | $332.71 | +151% | Bullish | |
| $188.08 | $253.93 | $369.61 | +175% | Bullish | |
| $278.91 | $392.74 | $599.07 | +326% | Bullish | |
| $532.28 | $803.85 | $1,314.36 | +772% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $75.87 | $92.21 | $109.11 | +0.00% |
| August 2026 | $80.70 | $94.46 | $112.95 | +2.44% |
| September 2026 | $81.06 | $95.33 | $114.89 | +0.92% |
| October 2026 | $79.92 | $94.38 | $114.50 | -1.00% |
| November 2026 | $80.87 | $95.84 | $116.90 | +1.54% |
| December 2026 | $83.07 | $98.76 | $121.08 | +3.05% |
Click any year to see its month-by-month EW forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Edwards Lifesciences Corporation's 2026 outlook centres on $92.21, within a $75.87 to $121.08 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, EW could reach as high as $140.36, with a base case around $109.96 and support toward $90.06 — roughly +19% from $92.21. Price action looks broadly range-bound.
Expect EW to range from $91.94 to $149.94 through 2028. The $114.36 average target implies a +24% move from current prices. That is up +4% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The EW price prediction for 2029 points to an average of $131.82 (low $104.36, high $176.51) — a potential gain of +43% on today's $92.21. Momentum favours further upside here.
In 2030, EW is projected to trade between $116.11 and $202.61, averaging $148.64 — a potential gain of +61% from today's $92.21. That is up +13% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Edwards Lifesciences Corporation's 2031 outlook centres on $177.81, within a $137.22 to $246.21 range. That is up +20% on the projected 2030 average. That marks a +93% change versus current levels. Momentum favours further upside here.
By 2032, EW could reach as high as $293.14, with a base case around $208.74 and support toward $159.29 — roughly +126% from $92.21. Buyers look set to stay in control over this stretch.
Expect EW to range from $160.76 to $302.84 through 2033. The $212.89 average target implies a +131% move from current prices. That is up +2% on the projected 2032 average. Momentum favours further upside here.
The EW price prediction for 2034 points to an average of $231.13 (low $172.81, high $332.71) — a potential gain of +151% on today's $92.21. Buyers look set to stay in control over this stretch.
In 2035, EW is projected to trade between $188.08 and $369.61, averaging $253.93 — a potential gain of +175% from today's $92.21. That is up +10% on the projected 2034 average. Momentum favours further upside here.
Edwards Lifesciences Corporation's 2040 outlook centres on $392.74, within a $278.91 to $599.07 range. That is up +55% on the projected 2035 average. That marks a +326% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, EW could reach as high as $1,314.36, with a base case around $803.85 and support toward $532.28 — roughly +772% from $92.21. Momentum favours further upside here.
Investing $1,000 in EW today (≈ 10.844811 EW) could be worth
$8,717.65
+$7,717.65 (+772%) by 2050 · US Dollar
Based on the average projected EW price of $803.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EWwould be worth at today's price.
$1,000 invested in EW on Jul 10, 2025 (≈ 12.690355 EW) would be worth
$1,170.18
+$170.18 (+17.0%) today · 1.17× · US Dollar
Based on a EW entry price of $78.8 vs. today's $92.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $94.37 | $977.11 | -2.3% |
| 1 month ago | $85.98 | $1,072.46 | +7.2% |
| 3 months ago | $77.87 | $1,184.15 | +18.4% |
| 6 months ago | $83.01 | $1,110.83 | +11.1% |
| 1 year ago | $78.8 | $1,170.18 | +17.0% |
| All time (5.0y) ago | $106.74 | $863.87 | -13.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EW forecast.
Our base-case forecast reaches $180.00 around 2032.
Implied market cap at $180.00: $103.64B
The multi‑year forecast depicts a bullish trajectory after 2026. In 2026 the average is $94.37 with min $75.87 and max $125.36 and ROI 0. In 2027 the average is $114.48 with ROI 21.3 and bullish sentiment, followed by 2028 avg $121.75 (ROI 29), 2029 avg $141.65 (ROI 50.1), 2030 avg $162.16 (ROI 71.8), 2031 avg $196.75 (ROI 108.5), 2032 avg $230.21 (ROI 143.9), 2033 avg $235.91 (ROI 150), 2034 avg $260.33 (ROI 175.9), 2035 avg $286.09 (ROI 203.2).
The forecast continues with 2040 avg $454.30 (ROI 381.4) and 2050 avg $952.20 (ROI 909), with max values rising to $221.13 by 2030 and $1,557.16 by 2050. These are estimates, not guarantees, and imply substantial long‑term upside with bullish sentiment persisting into the 2040s and 2050s.
Tap a question to reveal the answer.
2030 avg $162.16; min $126.63; max $221.13; ROI 71.8; sentiment BULLISH.
The forecast shows neutral in 2026 with an average near $94.37, then a bullish trajectory from 2027 onward with averages rising to $114.48 (2027), $121.75 (2028), $141.65 (2029), $162.16 (2030) and up to $952.20 (2050); ROI grows to 21.3 in 2027 and to 909 by 2050, with sentiment BULLISH in the later years.
Yes—the 2050 forecast max is $1,557.16 with a bullish sentiment and ROI of 909.
Current price $94.37; Market cap $54.34B.
RSI14 70; SMA50 $85.23; SMA200 $82.45; Support $82.97; Resistance $94.37; 30-day range low $86.15 high $103.37; Sentiment BULLISH.
Edwards Lifesciences Corporation Community Discussion
0Share your Edwards Lifesciences Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.